Pipeline Moves: Pfizer scores in Phase II cancer cachexia trial
This week on Pipeline Moves, the Clinical Trials Arena team investigates candidates in oncology, central nervous system and women’s health.
30 September 2024
30 September 2024
This week on Pipeline Moves, the Clinical Trials Arena team investigates candidates in oncology, central nervous system and women’s health.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Per our analysis, drug sales in the COPD drug market is expected to grow at a steady rate between 2023 and 2033, with an overall CAGR of 10.3% over the forecast period. In 2023, GlobalData estimated the total COPD market to be valued at $11.5 billion across the 7MM, with the US accounting for 79.4% of the market. Key topics covered in the report include an assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU and Japan over the 10-year forecast period.
Per our analysis, drug sales in the COPD drug market is expected to grow at a steady rate between 2023 and 2033, with an overall CAGR of 10.3% over the forecast period. In 2023, GlobalData estimated the total COPD market to be valued at $11.5 billion across the 7MM, with the US accounting for 79.4% of the market. Key topics covered in the report include an assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU and Japan over the 10-year forecast period.
Per our analysis, drug sales in the COPD drug market is expected to grow at a steady rate between 2023 and 2033, with an overall CAGR of 10.3% over the forecast period. In 2023, GlobalData estimated the total COPD market to be valued at $11.5 billion across the 7MM, with the US accounting for 79.4% of the market. Key topics covered in the report include an assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU and Japan over the 10-year forecast period.
Per our analysis, drug sales in the COPD drug market is expected to grow at a steady rate between 2023 and 2033, with an overall CAGR of 10.3% over the forecast period. In 2023, GlobalData estimated the total COPD market to be valued at $11.5 billion across the 7MM, with the US accounting for 79.4% of the market. Key topics covered in the report include an assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU and Japan over the 10-year forecast period.
Per our analysis, drug sales in the COPD drug market is expected to grow at a steady rate between 2023 and 2033, with an overall CAGR of 10.3% over the forecast period. In 2023, GlobalData estimated the total COPD market to be valued at $11.5 billion across the 7MM, with the US accounting for 79.4% of the market. Key topics covered in the report include an assessment of marketed and pipeline therapies, unmet needs, current and future players and market outlook for the US, 5EU and Japan over the 10-year forecast period.
Give your business an edge with our leading industry insights.